Search Results

Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12.

• Authors : Morillon II, Y. Maurice¹; Zhen Su²; Schlom, Jeffrey¹

Subjects: *BLADDER cancer; *NON-muscle invasive bladder cancer; *BCG vaccines

• Source: Journal for ImmunoTherapy of Cancer. 12/1/2019, Vol. 7 Issue 1, p1-11. 11p.

Record details

Biomarkers for immunotherapy in bladder cancer: a moving target.

• Authors : Aggen, David H.¹ ; Drake, Charles G.¹

Subjects: *BLADDER cancer treatment; *CANCER immunotherapy; *BIOMARKERS

• Source: Journal for ImmunoTherapy of Cancer. 11/21/2017, Vol. 5, p1-13. 13p.

Record details

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.

• Authors : Kamat, Ashish M.¹ ; Bellmunt, Joaquim²; Galsky, Matthew D.³

Subjects: *IMMUNOTHERAPY; *BLADDER cancer treatment; *BCG vaccines

• Source: Journal for ImmunoTherapy of Cancer. 8/15/2017, Vol. 5, p1-16. 16p.

Record details

Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.

Subjects: *IMMUNOTHERAPY; *BLADDER cancer treatment

• Source: Journal for ImmunoTherapy of Cancer. 9/28/2017, Vol. 5, p1-2. 2p.

Record details

Immune checkpoint inhibitor-related acral vasculitis.

• Authors : Comont, Thibault¹ ; Sibaud, Vincent² ; Mourey, Loïc³

Subjects: *IPILIMUMAB; *BLADDER cancer

• Source: Journal for ImmunoTherapy of Cancer. 11/16/2018, Vol. 6 Issue 1, pN.PAG-N.PAG. 1p.

Record details

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.

• Authors : Sweis, Randy F.¹ ; Zha, Yuanyuan²; Pass, Lomax³

Subjects: *IMMUNOTHERAPY; *BLADDER cancer

• Source: Journal for ImmunoTherapy of Cancer. 4/4/2018, Vol. 6, pN.PAG-N.PAG. 1p.

Record details

The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer.

• Authors : Daniele, Bruno¹; Sangro, Bruno²; Petrylak, Daniel³

Subjects: *CANCER immunotherapy; *LIVER cancer; *BLADDER cancer treatment

• Source: Journal for ImmunoTherapy of Cancer. 1/19/2016, Vol. 4, p1-6. 6p.

Record details

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.

• Authors : Kvarnhammar, Anne Månsson¹ ; Veitonmäki, Niina¹; Hägerbrand, Karin¹

Subjects: *BISPECIFIC antibodies; *CYTOTOXIC T lymphocyte-associated molecule-4; *REGULATORY T cells

• Source: Journal for ImmunoTherapy of Cancer. 12/1/2019, Vol. 7 Issue 1, p1-14. 14p.

Record details

DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes.

• Authors : Vidotto, Thiago¹; Nersesian, Sarah²; Graham, Charles²

Subjects: *GENE expression; *REGULATOR genes; *DNA repair

• Source: Journal for ImmunoTherapy of Cancer. 12/1/2019, Vol. 7 Issue 1, p1-12. 12p.

Record details

The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.

• Authors : Davis, Andrew A.^1,2 (AUTHOR); Patel, Vaibhav G.³ (AUTHOR)

Subjects: *TRIPLE-negative breast cancer; *DRUG approval; *NON-small-cell lung carcinomaUNITED States. Food & Drug Administration

• Source: Journal for ImmunoTherapy of Cancer. 10/26/2019, Vol. 7 Issue 1, pN.PAG-N.PAG. 1p.

Record details